✦ LIBER ✦

Epirubicin, cyclophosphamide and weekly paclitaxel as neoadjuvant chemotherapy for stage II and III breast cancer

✍ Scribed by David Aguiar Bujanda; Uriel Bohn Sarmiento; Miguel Ángel Cabrera Suárez; Marta Pavcovich Ruiz; Miguel Ángel Limeres González; José Aguiar Morales

Book ID: 106123553
Publisher: Springer-Verlag
Year: 2006
Tongue: English
Weight: 212 KB
Volume: 132
Category: Article
ISSN: 1432-1335
DOI: 10.1007/s00432-006-0079-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Taxane-based chemotherapy enhances respo

Taxane-based chemotherapy enhances response to neoadjuvant treatment for stage II and III breast cancer

✍ J. M. Andrade; H. H. A. Carrara; F. F. Pimentel; H. R. C. Marana; A. H. Macchett 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 160 KB

Phase I trial of adjuvant chemotherapy w

Phase I trial of adjuvant chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil (CEF) for stage II breast cancer

✍ Stephen E. Jones; Robert G. Mennel; George N. Peters; Mary Alice Westrick; Barry 📂 Article 📅 1988 🏛 Springer US 🌐 English ⚖ 263 KB

Epirubicin is a new anthracycline with a potentially more favorable toxicity profile than the parent compound, doxorubicin. Accordingly, the feasibility and toxicity of 6 courses of adjuvant chemotherapy with cyclophosphamide (C), epirubicin (E), and 5-fluorouracil (F) were assessed in 10 patients w

MRI Phenotype Is Associated With Respons

MRI Phenotype Is Associated With Response to Doxorubicin and Cyclophosphamide Neoadjuvant Chemotherapy in Stage III Breast Cancer

✍ Laura Esserman; Elizabeth Kaplan; Savanah Partridge; Debasish Tripathy; Hope Rug 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 882 KB

Feasibility and Outcomes of Concurrent P

Feasibility and Outcomes of Concurrent Paclitaxel Chemotherapy and Radiotherapy for Node-positive Stage II-III Breast Cancer

✍ W.C. Chen; J. Kim; E. Kim; P. Silverman; B. Overmoyer; B.W. Cooper; S. Anthony; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 39 KB

Two years of cyclophosphamide and 5-fluo

Two years of cyclophosphamide and 5-fluorouracil as adjuvant chemotherapy for stage II and III breast carcinoma

✍ Dr. E. Caceres; S. Valdivia; M. Cotrina; M. Lingan; L. Leon; M. Gamboa; L. Oliva 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 392 KB

The results after 6 years of a prospective clinical trial of adjuvant chemotherapy with a regimen of two drugs--cyclophosphamide and 5-fluorouracil (CF)-- for 2 years in 97 women with stage II or III breast cancer are reported. Eligible patients were free from distant metastases. All patients began

Biweekly docetaxel and gemcitabine as ne

Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage II and III breast cancer patients: results of a phase II study

✍ L. G. Estévez; P. Sánchez-Rovira; M. Dómine; A. León; I. Calvo; A. Jaén; V. Casa 📂 Article 📅 2007 🏛 Springer Milan 🌐 Spanish ⚖ 80 KB